Prognostic Implication of KRASG12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands

With the approval of G12C inhibitors as the second line of treatment for KRASG12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to understand the prognostic implication of KRASG12C in the current first line of treatment. We compared overall survival (OS) of patients with stage IV KRASG12C-mutated NSCLC to those with a KRASnon-G12C mutation in a first-line setting of (chemo)immunotherapy.